MedTrace Logo

Linezolid for Syphilis Pilot Study

NCT05548426 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-03-12

No results posted yet for this study

Summary

The study aims to evaluate the efficacy of linezolid for the treatment of syphilis.

Conditions

  • Syphilis

Interventions

DRUG

Group B, Linezolid 10d

Oral Linezolid 600mg, taken twice a day for 10 days

DRUG

Group A, Penicillin

Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU

Sponsors & Collaborators

  • University of Southern California

    lead OTHER

Principal Investigators

  • Jeffrey D Klausner, MD MPH · University of Southern California

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-28
Primary Completion
2026-08-31
Completion
2026-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05548426 on ClinicalTrials.gov